● pepmg Research Desk · Peer-reviewed evidence review
What the research says about prostamax
A neutral summary of the peer-reviewed literature on prostamax, a synthetic Lys-Glu-Asp-Pro short-peptide bioregulator studied almost entirely by a single research lineage in animal and in-vitro models, including cultures of ex-vivo human lymphocytes from elderly donors. There are no controlled human trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Prostamax is described in the literature as a synthetic oligopeptide bioregulator with the sequence Lys-Glu-Asp-Pro, in the family of Khavinson-type short peptides, studied in the context of prostate tissue [3][5].
- The evidence is entirely preclinical: an animal organotypic-culture study reports a stimulating effect on prostate-tissue explants, while most of the literature is in-vitro work on human lymphocyte chromatin from elderly donors [1][2][3][4].
- Those human-cell studies report activation of ribosomal genes, decondensation of densely packed chromatin, and changes in chromosome parameters; there are no controlled human trials of prostamax as an administered compound, and the work comes essentially from a single research lineage [2][4].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What prostamax is
Prostamax is characterized in the literature as a synthetic oligopeptide bioregulator with the sequence Lys-Glu-Asp-Pro, one of a family of Khavinson-type short peptides reported to act tissue-specifically in organ culture, with prostamax studied in the context of prostate tissue [3][5]. Organ-culture work describes these peptides producing a stimulating effect in cultures of the matched tissue rather than a general effect across tissues [1].
Prostamax is a research compound, not an approved medicine. Material sold by third-party research-chemical vendors is offered for laboratory and research use only.
What the research has measured
Preclinical onlyThe evidence for prostamax is entirely preclinical. In organotypic tissue culture of explants from young and aged rats, prostamax was among synthetic peptides reported to produce a stimulating effect at a very low concentration (0.05 ng/ml) in the matched tissue, described in the context of reparative processes during aging [1].
Most of the human-material work studied lymphocyte chromatin in cell culture. In leukocytes from subjects aged 75 to 88, prostamax was among short peptides reported to activate ribosomal genes and to induce decondensation of densely packed chromatin, with prostamax treatment specifically reported to decondense pericentromeric structural chromatin of chromosome 1 [2]. A microcalorimetry study reported that prostamax shifted the thermal-denaturation profile of human lymphocyte chromatin, which the authors linked to partial relaxation of the chromatin fiber [3]. A related microcalorimetric study examined prostamax together with copper and cadmium ions in cultures of blood lymphocytes from aging people and reported that the metal ions, not prostamax, drove the observed changes in heterochromatin condensation at the concentrations tested [4].
One study measured chromosome-level endpoints. In cells from individuals aged 75 to 86, prostamax was reported to increase the frequency of sister-chromatid exchanges and of silver-positive nucleolar organizer regions and to reduce large pericentromeric heterochromatin segments on chromosomes 1 and 9, which the authors interpreted as a deheterochromatinizing effect that could release age-repressed genes [5]. These are measured endpoints in cultured human cells, not administration of prostamax to people.
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of prostamax, and the abstracts reviewed here contain no human adverse-event data. Nothing in this literature reports rates of side effects in people.
The preclinical abstracts describe measured biological effects rather than a formal toxicity profile. The organotypic study reports stimulation of prostate-tissue explant growth [1], and the human-cell studies report changes in chromatin structure and chromosome parameters such as increased sister-chromatid exchange frequency [2][5]. These are measured effects in animal and cultured-cell models, not a human safety characterization, and the abstracts do not report toxicity testing.
Because the data are preclinical, nothing here should be read as a safety statement for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for prostamax is characterized as preclinical: it consists of one animal organotypic-culture study and several pieces of in-vitro work on cultured human lymphocytes from elderly donors (chromatin structure, ribosomal-gene activity, and chromosome parameters), with no controlled human trials of prostamax as an administered compound and a literature drawn essentially from a single research lineage [1][2][3][5]. "Preclinical" describes the design and scope of the published studies, not an endorsement, and the scope is narrow: the human-cell findings are in cultured cells, not in people.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 5
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
- Effects of short peptides on lymphocyte chromatin in senile subjects.
- [The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ].
- Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax.
- [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)].
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.